Business Context and Reporting Period
This Form 8-K Current Report was filed by Collegium Pharmaceutical, Inc. on August 4, 2015. The filing discloses the approval of new executive employment agreements for the Company's Chief Executive Officer, Michael Heffernan, and Chief Financial Officer, Paul Brannelly, by the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
- CEO Base Salary: $488,800 annually.
- CFO Base Salary: $325,000 annually.
- CEO Target Bonus: 50% of base salary.
- CFO Target Bonus: 35% of base salary.
Material Changes
The material change reported is the formalization of executive compensation structures effective August 4, 2015. The agreements establish specific severance packages and vesting accelerations triggered by termination without cause, resignation for good reason, or a change in control.
Outlook, Risks, and Unusual Items
Severance Provisions:
- CEO (Heffernan): Eligible for 12 months of base salary continuation, COBRA premium waiver, full equity vesting, and a lump-sum target bonus upon termination without cause or resignation for good reason. In the event of a change in control followed by such termination within 12 months, salary continuation extends to 18 months.
- CFO (Brannelly): Eligible for 9 months of base salary continuation and COBRA premium waiver upon termination without cause or resignation for good reason. In the event of a change in control followed by such termination within 12 months, salary continuation extends to 12 months.
Covenants: Both executives are subject to non-solicitation and non-competition covenants for 12 months (CEO) and 9 months (CFO) following cessation of employment.
Investor Verification Checklist
- Review the full text of Employment Agreements filed as Exhibit 10.1 and 10.2 for specific definitions of "Cause" and "Good Reason."
- Verify the Company's current cash position to assess the ability to fund potential severance obligations.
- Confirm the status of unvested equity awards for both executives to understand the potential dilution impact of immediate vesting.
- Check for any pending change in control transactions that could trigger the enhanced severance provisions.